Am­gen’s win for a Ste­lara in­ter­change­able biosim­i­lar prompts ques­tions about ‘mean­ing­ful com­pe­ti­tion’ un­der IRA

The FDA ap­proval of Am­gen’s in­ter­change­able Ste­lara biosim­i­lar is rais­ing broad­er ques­tions about how po­ten­tial com­pe­ti­tion could im­pact Medicare price ne­go­ti­a­tions for John­son & John­son’s block­buster.

Ste­lara (ustek­inum­ab) was first ap­proved in 2009 and last year gen­er­at­ed near­ly $6.4 bil­lion in US sales in a slate of in­flam­ma­to­ry con­di­tions, ac­cord­ing to J&J. It al­so cost Medicare Part D $2.6 bil­lion be­tween June 2022 and May of this year, CMS said, putting it on the agency’s list of 10 drugs sub­ject to price ne­go­ti­a­tions un­der the In­fla­tion Re­duc­tion Act.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA